- Home
- CANF vs NXGL Comparison
CANF vs NXGL Comparison
Compare CANF & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | NXGL |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | Israel | United States |
| Employees | N/A | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 4.9M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | NXGL |
|---|---|---|
| Price | $3.21 | $0.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $50.00 | $2.00 |
| AVG Volume (30 Days) | ★ 1.8M | 330.7K |
| Earning Date | 03-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,715,455.50 | $50.77 |
| Revenue Next Year | $101.06 | $46.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.41 |
| 52 Week High | $10.40 | $2.89 |
Technical Indicators
Market Signals| Indicator | CANF | NXGL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.